

Isabella Russo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3794406/publications.pdf>

Version: 2024-02-01

83
papers

3,068
citations

126858

33
h-index

175177

52
g-index

84
all docs

84
docs citations

84
times ranked

4607
citing authors

#	ARTICLE	IF	CITATIONS
1	p140Cap Controls Female Fertility in Mice Acting via Glutamatergic Afference on Hypothalamic Gonadotropin-Releasing Hormone Neurons. <i>Frontiers in Neuroscience</i> , 2022, 16, 744693.	1.4	0
2	Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis. <i>Antioxidants</i> , 2022, 11, 569.	2.2	8
3	PCSK9 Biology and Its Role in Atherothrombosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5880.	1.8	70
4	Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7032.	1.8	5
5	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7193.	1.8	26
6	Prothrombotic Phenotype in COVID-19: Focus on Platelets. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13638.	1.8	21
7	Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 282-291.	1.1	44
8	Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4983.	1.8	10
9	Ticagrelor Conditioning Effects Are Not Additive to Cardioprotection Induced by Direct NLRP3 Inflammasome Inhibition: Role of RISK, NLRP3, and Redox Cascades. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-12.	1.9	19
10	Influence of Cardiometabolic Risk Factors on Platelet Function. <i>International Journal of Molecular Sciences</i> , 2020, 21, 623.	1.8	66
11	In-Silico Transcriptome Analyses of Hemostasis Triggers in Inflamed Vs Normal Mucosa of IBD Patients. <i>Blood</i> , 2020, 136, 19-20.	0.6	0
12	Nuclear-cytoplasmic Shuttling in Chronic Myeloid Leukemia: Implications in Leukemia Maintenance and Therapy. <i>Cells</i> , 2019, 8, 1248.	1.8	3
13	Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. <i>Thrombosis Research</i> , 2019, 180, 74-85.	0.8	8
14	Transferrin Saturation Inversely Correlates with Platelet Function. <i>Thrombosis and Haemostasis</i> , 2019, 119, 766-778.	1.8	4
15	p140Cap Regulates GABAergic Synaptogenesis and Development of Hippocampal Inhibitory Circuits. <i>Cerebral Cortex</i> , 2019, 29, 91-105.	1.6	13
16	Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	50
17	Cardioprotective Properties of Human Platelets Are Lost in Uncontrolled Diabetes Mellitus: A Study in Isolated Rat Hearts. <i>Frontiers in Physiology</i> , 2018, 9, 875.	1.3	18
18	Effects of a 8-week treatment with monoclonal antibody anti-PCSK9 therapy on platelet function in subjects affected by familial hypercholesterolemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, e7-e8.	1.1	0

#	ARTICLE	IF	CITATIONS
19	The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. <i>Nature Communications</i> , 2017, 8, 14797.	5.8	26
20	Effects of PCSK9 inhibitors on platelet function in adults with hypercholesterolemia. <i>Atherosclerosis</i> , 2017, 263, e30-e31.	0.4	6
21	Platelets, diabetes and myocardial ischemia/reperfusion injury. <i>Cardiovascular Diabetology</i> , 2017, 16, 71.	2.7	73
22	Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1115-1128.	1.8	61
23	In Type 2 Diabetes mellitus the GLP-1 effects on platelets are impaired. <i>Atherosclerosis</i> , 2016, 252, e257-e258.	0.4	2
24	LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate. <i>Molecular Neurodegeneration</i> , 2016, 11, 1.	4.4	128
25	Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain. <i>Journal of Neurochemistry</i> , 2015, 135, 1242-1256.	2.1	57
26	Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF- κ B p50 signaling in cultured microglia cells. <i>Journal of Neuroinflammation</i> , 2015, 12, 230.	3.1	99
27	Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies. <i>Medicinal Research Reviews</i> , 2015, 35, 968-1031.	5.0	43
28	LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. <i>Frontiers in Molecular Neuroscience</i> , 2014, 7, 49.	1.4	82
29	A Short-Term Incubation with High Glucose Impairs VASP Phosphorylation at Serine 239 in response to the Nitric Oxide/cGMP Pathway in Vascular Smooth Muscle Cells: Role of Oxidative Stress. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	5
30	A novel truncated form of eNOS associates with altered vascular function. <i>Cardiovascular Research</i> , 2014, 101, 492-502.	1.8	17
31	LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?. <i>Journal of Neuroinflammation</i> , 2014, 11, 52.	3.1	148
32	Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. <i>Neurobiology of Disease</i> , 2014, 71, 62-73.	2.1	48
33	Leptin and Vascular Smooth Muscle Cells. <i>Current Pharmaceutical Design</i> , 2014, 20, 625-634.	0.9	30
34	AMPA Receptor Properties are Modulated in the Early Stages Following Pilocarpine-induced Status Epilepticus. <i>NeuroMolecular Medicine</i> , 2013, 15, 324-338.	1.8	33
35	Oleic Acid Increases Synthesis and Secretion of VEGF in Rat Vascular Smooth Muscle Cells: Role of Oxidative Stress and Impairment in Obesity. <i>International Journal of Molecular Sciences</i> , 2013, 14, 18861-18880.	1.8	11
36	Modulation of dendritic AMPA receptor mRNA trafficking by RNA splicing and editing. <i>Nucleic Acids Research</i> , 2013, 41, 617-631.	6.5	35

#	ARTICLE	IF	CITATIONS
37	Effects of High Glucose on Vascular Endothelial Growth Factor Synthesis and Secretion in Aortic Vascular Smooth Muscle Cells from Obese and Lean Zucker Rats. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9478-9488.	1.8	14
38	The Prothrombotic Tendency in Metabolic Syndrome: Focus on the Potential Mechanisms Involved in Impaired Haemostasis and Fibrinolytic Balance. <i>Scientifica</i> , 2012, 2012, 1-17.	0.6	34
39	3,6-dithiothalidomide, a new TNF α synthesis inhibitor, attenuates the effect of A β ⁴² intracerebroventricular injection on hippocampal neurogenesis and memory deficit. <i>Journal of Neurochemistry</i> , 2012, 122, 1181-1192.	2.1	61
40	Tumor necrosis factor α synthesis inhibitor 3,6-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. <i>Journal of Neuroinflammation</i> , 2012, 9, 106.	3.1	179
41	High Glucose Inhibits the Aspirin-Induced Activation of the Nitric Oxide/cGMP/cGMP-Dependent Protein Kinase Pathway and Does Not Affect the Aspirin-Induced Inhibition of Thromboxane Synthesis in Human Platelets. <i>Diabetes</i> , 2012, 61, 2913-2921.	0.3	27
42	Effects of neuroinflammation on the regenerative capacity of brain stem cells. <i>Journal of Neurochemistry</i> , 2011, 116, 947-956.	2.1	135
43	Nitric oxide activates PI3-K and MAPK signalling pathways in human and rat vascular smooth muscle cells: Influence of insulin resistance and oxidative stress. <i>Atherosclerosis</i> , 2011, 216, 44-53.	0.4	40
44	Cyclooxygenase-1 is involved in the inhibition of hippocampal neurogenesis after lipopolysaccharide-induced neuroinflammation. <i>Cell Cycle</i> , 2011, 10, 2568-2573.	1.3	36
45	AMPA Receptor Regulation at the mRNA and Protein Level in Rat Primary Cortical Cultures. <i>PLoS ONE</i> , 2011, 6, e25350.	1.1	36
46	In Central Obesity, Weight Loss Restores Platelet Sensitivity to Nitric Oxide and Prostacyclin. <i>Obesity</i> , 2010, 18, 788-797.	1.5	59
47	The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy with Dipeptidyl Peptidase-4 Inhibitors and Metformin. <i>Clinical Medicine Insights Therapeutics</i> , 2010, 2, CMT.S3420.	0.4	1
48	Adipocytokines in Atherothrombosis: Focus on Platelets and Vascular Smooth Muscle Cells. <i>Mediators of Inflammation</i> , 2010, 2010, 1-26.	1.4	55
49	The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus. <i>Current Vascular Pharmacology</i> , 2010, 8, 327-337.	0.8	59
50	Role of NMDA receptor in homocysteine-induced activation of Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase pathways in cultured human vascular smooth muscle cells. <i>Thrombosis Research</i> , 2010, 125, e23-e32.	0.8	26
51	Platelet dysfunction in central obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 440-449.	1.1	117
52	Contribution of insulin resistance to vascular dysfunction. <i>Archives of Physiology and Biochemistry</i> , 2009, 115, 199-217.	1.0	34
53	Sodium azide, a bacteriostatic preservative contained in commercially available laboratory reagents, influences the responses of human platelets via the cGMP/PKG/VASP pathway. <i>Clinical Biochemistry</i> , 2008, 41, 343-349.	0.8	14
54	Resistance to the Nitric Oxide/Cyclic Guanosine 5'-Monophosphate/Protein Kinase G Pathway in Vascular Smooth Muscle Cells from the Obese Zucker Rat, a Classical Animal Model of Insulin Resistance: Role of Oxidative Stress. <i>Endocrinology</i> , 2008, 149, 1480-1489.	1.4	44

#	ARTICLE	IF	CITATIONS
55	Resistance to Aspirin and Thienopyridines in Diabetes Mellitus and Metabolic Syndrome. <i>Current Vascular Pharmacology</i> , 2008, 6, 313-328.	0.8	30
56	Platelet Resistance to the Antiaggregatory Cyclic Nucleotides in Central Obesity Involves Reduced Phosphorylation of Vasodilator-Stimulated Phosphoprotein. <i>Clinical Chemistry</i> , 2007, 53, 1053-1060.	1.5	32
57	Relevance of the Vascular Effects of Insulin in the Rationale of its Therapeutical Use. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2007, 7, 228-249.	0.2	23
58	Insulin activates hypoxia-inducible factor-1 α in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. <i>Diabetologia</i> , 2006, 49, 1049-1063.	2.9	47
59	Sodium Azide in Commercially Available C-Reactive Protein Preparations Does Not Influence Matrix Metalloproteinase-2 Synthesis and Release in Cultured Human Aortic Vascular Smooth Muscle Cells. <i>Clinical Chemistry</i> , 2006, 52, 1200-1201.	1.5	7
60	Platelet Resistance to the Anti-Aggregating Agents in the Insulin Resistant States. <i>Current Diabetes Reviews</i> , 2006, 2, 409-430.	0.6	27
61	High glucose rapidly activates the nitric oxide/cyclic nucleotide pathway in human platelets via an osmotic mechanism. <i>Thrombosis and Haemostasis</i> , 2005, 93, 517-526.	1.8	20
62	C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. <i>Translational Research</i> , 2005, 146, 287-298.	2.4	35
63	Homocysteine rapidly increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1285-1293.	1.8	27
64	Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. <i>European Journal of Clinical Investigation</i> , 2004, 34, 482-489.	1.7	49
65	Insulin activates vascular endothelial growth factor in vascular smooth muscle cells: influence of nitric oxide and of insulin resistance. <i>European Journal of Clinical Investigation</i> , 2004, 34, 664-673.	1.7	75
66	The activity of constitutive nitric oxide synthase is increased by the pathway cAMP/cAMP-activated protein kinase in human platelets. New insights into the antiaggregating effects of cAMP-elevating agents. <i>Thrombosis Research</i> , 2004, 114, 265-273.	0.8	40
67	40th EASD Annual Meeting of the European Association for the Study of Diabetes. <i>Diabetologia</i> , 2004, 47, A1-A464.	2.9	41
68	Comparison between the effects of the rapid recombinant insulin analog Lispro (Lys B28, Pro B29) and those of human regular insulin on platelet cyclic nucleotides and aggregation. <i>Thrombosis Research</i> , 2003, 109, 323-327.	0.8	4
69	Platelet resistance to the antiaggregating effect of N-acetyl-l-cysteine in obese, insulin-resistant subjects. <i>Thrombosis Research</i> , 2003, 110, 39-46.	0.8	21
70	Insulin Stimulates Glucose Transport Via Nitric Oxide/Cyclic GMP Pathway in Human Vascular Smooth Muscle Cells. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 2215-2221.	1.1	86
71	Insulin influences the nitric oxide cyclic nucleotide pathway in cultured human smooth muscle cells from corpus cavernosum by rapidly activating a constitutive nitric oxide synthase. <i>European Journal of Endocrinology</i> , 2002, 147, 689-700.	1.9	13
72	Adenosine increases human platelet levels of 3 β ,5 α -cGMP through nitric oxide. <i>Thrombosis Research</i> , 2002, 105, 71-78.	0.8	75

#	ARTICLE	IF	CITATIONS
73	Comparison between the effects of the rapid recombinant insulin analog aspart and those of human regular insulin on platelet cyclic nucleotides and aggregation. <i>Thrombosis Research</i> , 2002, 107, 31-37.	0.8	16
74	Catecholamines, via β_2 -adrenoceptors, Increase Intracellular Concentrations of 3',5'-cyclic Guanosine Monophosphate (cGMP) through Nitric Oxide in Human Platelets. <i>Thrombosis and Haemostasis</i> , 2002, 87, 539-540.	1.8	12
75	Catecholamines, via beta-adrenoceptors, increase intracellular concentrations of 3',5'-cyclic guanosine monophosphate (cGMP) through nitric oxide in human platelets. <i>Thrombosis and Haemostasis</i> , 2002, 87, 539-40.	1.8	4
76	Studies on Inhibition of Human Platelet Function by Sodium Nitroprusside. Kinetic Evaluation of the Effect on Aggregation and Cyclic Nucleotide Content. <i>Thrombosis Research</i> , 2001, 102, 319-330.	0.8	18
77	N-acetyl-L-cysteine exerts direct anti-aggregating effect on human platelets. <i>European Journal of Clinical Investigation</i> , 2001, 31, 452-461.	1.7	39
78	L-Arginine Modulates Aggregation and Intracellular Cyclic 3',5'-Guanosine Monophosphate Levels in Human Platelets. <i>Thrombosis Research</i> , 1999, 94, 307-316.	0.8	22
79	Influence of protamine on adhesion, chemotaxis and proliferation of human vascular smooth muscle cells. <i>Diabetologia</i> , 1997, 40, 67-75.	2.9	9
80	Nonenzymatic glycation of fibronectin impairs adhesive and proliferative properties of human vascular smooth muscle cells. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 285-292.	1.5	12
81	Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood. <i>Thrombosis Research</i> , 1995, 77, 399-410.	0.8	4
82	Insulin Stimulates the Polymorphonuclear Leukocyte Chemokinesis. <i>Hormone and Metabolic Research</i> , 1993, 25, 321-322.	0.7	11
83	Insulin, at Physiological Concentrations, Enhances the Polymorphonuclear Leukocyte Chemotactic Properties. <i>Hormone and Metabolic Research</i> , 1992, 24, 225-228.	0.7	29